伊布替尼-话题@MedSci

#伊布替尼#

88篇内容 | 1998人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1288714, encodeId=05cb1288e14d0, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=复发/难治CLL/SLL患者中比较伊布替尼和利妥昔单抗：一项随机开放性Ⅲ期研究, objectType=article, longId=116543, objectId=2f6e116543b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f6e116543b5, replyNumber=0, likeNumber=38, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f6e116543b5, moduleTitle=复发/难治CLL/SLL患者中比较伊布替尼和利妥昔单抗：一项随机开放性Ⅲ期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f6e116543b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288713, encodeId=3dfb1288e13d6, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=J Clin Oncol：BTK抑制剂伊布替尼在复发难治B细胞恶性肿瘤患者中具有显著的抗肿瘤活性, objectType=article, longId=116540, objectId=d02a116540e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d02a116540e5, replyNumber=0, likeNumber=35, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d02a116540e5, moduleTitle=J Clin Oncol：BTK抑制剂伊布替尼在复发难治B细胞恶性肿瘤患者中具有显著的抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d02a116540e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288712, encodeId=da6b1288e12c9, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=全球BTK抑制剂亿珂®（伊布替尼）在中国获批, objectType=article, longId=116538, objectId=1f31116538be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f31116538be, replyNumber=0, likeNumber=37, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f31116538be, moduleTitle=全球BTK抑制剂亿珂®（伊布替尼）在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f31116538be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288711, encodeId=47d91288e11ac, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=SPARK研究（MCL 2001）：伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究, objectType=article, longId=116537, objectId=dd4711653e32, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd4711653e32, replyNumber=0, likeNumber=29, createdTime=2017-10-19, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd4711653e32, moduleTitle=SPARK研究（MCL 2001）：伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd4711653e32)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288710, encodeId=4f851288e1046, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=伊布替尼单药在RR MCL患者中疗效：一项开放性多中心Ⅱ期研究首次研究及长期随访结果（PCYC-1104研究）, objectType=article, longId=113569, objectId=597e1135690b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597e1135690b, replyNumber=0, likeNumber=21, createdTime=2017-09-23, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597e1135690b, moduleTitle=伊布替尼单药在RR MCL患者中疗效：一项开放性多中心Ⅱ期研究首次研究及长期随访结果（PCYC-1104研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=597e1135690b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288709, encodeId=dfaf1288e09d4, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=伊布替尼VS西罗莫司在RR MCL患者中疗效：一项随机对照开放性多中心Ⅲ期研究(RAY研究, MCL 3001), objectType=article, longId=113568, objectId=9b57113568f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b57113568f5, replyNumber=0, likeNumber=23, createdTime=2017-09-23, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b57113568f5, moduleTitle=伊布替尼VS西罗莫司在RR MCL患者中疗效：一项随机对照开放性多中心Ⅲ期研究(RAY研究, MCL 3001), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b57113568f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288708, encodeId=21921288e085f, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究(SPARK研究, MCL 2001）, objectType=article, longId=113567, objectId=c69011356e79, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c69011356e79, replyNumber=0, likeNumber=19, createdTime=2017-09-23, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c69011356e79, moduleTitle=伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究(SPARK研究, MCL 2001）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c69011356e79)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288707, encodeId=6cdf1288e0753, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=重磅丨全球BTK抑制剂亿珂®（伊布替尼）在中国获批, objectType=article, longId=111399, objectId=185911139962, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=185911139962, replyNumber=0, likeNumber=22, createdTime=2017-09-01, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=185911139962, moduleTitle=重磅丨全球BTK抑制剂亿珂®（伊布替尼）在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=185911139962)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288706, encodeId=0b4c1288e0664, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=Blood：伊布替尼开启边缘区淋巴瘤无化疗时代, objectType=article, longId=96889, objectId=64fb968890c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64fb968890c, replyNumber=0, likeNumber=42, createdTime=2017-04-26, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64fb968890c, moduleTitle=Blood：伊布替尼开启边缘区淋巴瘤无化疗时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64fb968890c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288705, encodeId=09541288e05d8, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=一文纵览│伊布替尼治疗套细胞淋巴瘤的疗效, objectType=article, longId=94964, objectId=7a03949644f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a03949644f, replyNumber=0, likeNumber=27, createdTime=2017-04-08, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a03949644f, moduleTitle=一文纵览│伊布替尼治疗套细胞淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a03949644f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1288704, encodeId=bd121288e0430, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, objectTitle=Blood：如何治疗伊布替尼耐药的CLL患者？, objectType=article, longId=93305, objectId=e97a93305ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e97a93305ec, replyNumber=0, likeNumber=31, createdTime=2017-03-26, rootId=0, userName=hongbochen, userId=0a8e213, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e97a93305ec, moduleTitle=Blood：如何治疗伊布替尼耐药的CLL患者？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e97a93305ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

伊布替尼

2020-05-29

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

复发/难治CLL/SLL患者中比较伊布替尼和利妥昔单抗：一项随机开放性Ⅲ期研究

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

J Clin Oncol：BTK抑制剂伊布替尼在复发难治B细胞恶性肿瘤患者中具有显著的抗肿瘤活性

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

全球BTK抑制剂亿珂®（伊布替尼）在中国获批

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

SPARK研究（MCL 2001）：伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究

2017-10-19

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

伊布替尼单药在RR MCL患者中疗效：一项开放性多中心Ⅱ期研究首次研究及长期随访结果（PCYC-1104研究）

2017-09-23

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

伊布替尼VS西罗莫司在RR MCL患者中疗效：一项随机对照开放性多中心Ⅲ期研究(RAY研究, MCL 3001)

2017-09-23

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究(SPARK研究, MCL 2001）

2017-09-23

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

重磅丨全球BTK抑制剂亿珂®（伊布替尼）在中国获批

2017-09-01

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

Blood：伊布替尼开启边缘区淋巴瘤无化疗时代

2017-04-26

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

一文纵览│伊布替尼治疗套细胞淋巴瘤的疗效

2017-04-08

hongbochen (审核中...)

前往app查看评论内容

#伊布替尼#

Blood：如何治疗伊布替尼耐药的CLL患者？

2017-03-26

科室
- - 订阅+
  - 更多科室
工具
服务